Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions

Petrillo, Angelica; Pompella, Luca; Tirino, Giuseppe; Pappalardo, Annalisa; Laterza, Maria Maddalena; Caterino, Marianna; Orditura, Michele; Ciardiello, Fortunato; Lieto, Eva; Galizia, Gennaro; Castoro, Carlo; Vita, Ferdinando De

doi:10.3390/cancers11030399

Cited by 52 publications

(45 citation statements)

References 71 publications

(123 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the specific regimens for GSRC remain uncertain. 41,42 Several studies and retrospective analyses have shown that GSRC cannot benefit from chemotherapy or radiotherapy due to chemoresistance. 6,8,10 Chemotherapy GSRC has the characteristic of chemoresistance which has been confirmed by several studies.…”

Section: Adjuvant and Neoadjuvant Treatmentsmentioning

confidence: 99%

Gastric Signet Ring Cell Carcinoma: Current Management and Future Challenges

Zhu

et al. 2020

CMAR

View full text Add to dashboard Cite

Recent advances in the epidemiology, pathology, molecular mechanisms, and combined modality therapy (CMT) fields have shown that gastric signet ring cell carcinoma (GSRC) should be considered a distinct cancerous entity. Clinical management of this cancer is challenging, with chemoradioresistance and poor outcomes in advanced stages. Pathological and molecular sets of GSRC demonstrate different features of poor cohesion and differentiation according to the WHO, Japanese Gastric Cancer Association, and Laurén classifications. These features also result in poor response to adjuvant and neoadjuvant chemoradiotherapy. Certain studies of GSRC showed the disputed effectiveness of hyperthermic intraperitoneal chemotherapy and immunotherapy. Our aim was to discuss how an improved understanding of these therapeutic benefits may provide better treatment selection for patients, and therefore improve survival. The challenges in the new understanding of GSRC in routine practice and pathology, and the current limitations of treatment will also be discussed.

show abstract

Section: Adjuvant and Neoadjuvant Treatmentsmentioning

confidence: 99%

Gastric Signet Ring Cell Carcinoma: Current Management and Future Challenges

Zhu

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…1 These tumors are difficult to find because their early symptoms are not obvious, and most of these tumors would have already progressed to the late stage with lymphatic or distal metastasis by the time they are discovered. 2 Thus, simple surgical treatment cannot aid in full eradication of these tumors. To date, combinational chemotherapy forms the main part of the treatment strategy for advanced gastric cancer with less than 10% of 5-year survival rate.…”

Section: Introductionmentioning

confidence: 99%

The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric Cancer

Zhang

Niu

et al. 2020

OTT

View full text Add to dashboard Cite

The aim of this study was to investigate the antitumor effect of chidamide in combination with bortezomib on gastric cancer cell lines. Materials and Methods: First, the sensitivity and IC 50 values of chidamide and bortezomib in several gastric cancer cell lines (MGC-803, BGC-823, SGC-7901, and MKN45) were measured using the CCK-8 assay. Then, the relatively insensitive gastric cancer cell lines (MGC-803 and BGC-823) were treated with low concentrations of chidamide alone, bortezomib alone, or chidamide and bortezomib combination to detect the effects on cell proliferation, apoptosis, migration, and invasion. Finally, the inhibitory effect of the combined chidamide and bortezomib treatment on MGC-803 cells was verified in vivo through tumor formation experiments in nude mice. Results: Compared with low-dose chidamide or bortezomib alone, the low-dose drug combination significantly inhibited the proliferation, migration, and invasion of MGC-803 and BGC-823 cells and induced apoptosis of the cells. The effects of the low-dose chidamide and bortezomib combination reduced the growth on gastric cancer in vivo were investigated by using a subcutaneous tumor mouse model. Conclusion: Our results suggest that the combination of chidamide and bortezomib can significantly reduce the proliferation, invasion, and migration of MGC-803 and BGC-823 cells, providing a framework for the clinical evaluation of combined therapies for gastric cancers.

show abstract

“…In 2018, there were approximately 1.03 million new cases of GC globally and about 0.78 million deaths occurred because of GC [1]. Surgery-based comprehensive treatment is currently the main treatment approach for GC [2]. However, the postoperative 5-year survival rate of GC patients is relatively low.…”

Section: Introductionmentioning

confidence: 99%

Short-Term Heart Rate Variability and Blood Biomarkers of Gastric Cancer Prognosis

Wang

Shi

et al. 2020

IEEE Access

View full text Add to dashboard Cite

Inflammation, nutrition, and coagulation play significant roles in cancer prognosis. Autonomic function is also actively involved in tumorigenesis. Previous studies have shown that an elevated C-reactive protein (CRP) level, a serum marker for inflammation, is associated with low heart rate variability (HRV), a common clinical tool for the assessment of autonomic function. It is yet to be investigated whether HRV links to these prognostic factors in cancer patients. Sixty-one patients who were first diagnosed with gastric cancer (GC) were enrolled in this study. Fasting blood samples were collected in the morning seven days before surgery. Blood CRP, prealbumin (PA), and fibrinogen (FIB) were used to assess the inflammation level, nutritional status, and coagulation function respectively. Five-minute resting electrocardiogram (ECG) signals were collected one day before surgical treatment. Short-term HRV time-series were extracted from ECG recordings and were analyzed using commonly-used time-and frequency-domain parameters including standard deviation of normal-to-normal intervals (SDNN), root mean square of successive heartbeat interval differences (RMSSD), very-low-frequency power (VLF), low-frequency power (LF), high-frequency power (HF), total power (TP), LF power in normalized units (LF n.u.), HF power in normalized units (HF n.u.), and ratio of LF to HF (LF/HF). After adjusted for sex, age, body mass index, alcohol consumption, history of diabetes, left ventricular ejection fraction, and hemoglobin levels, our results demonstrated negative associations of HRV with levels of CRP and FIB, while positive associations between HRV and PA level, with effect sizes of as high as 35%-52% standard deviations (SD) changes in CRP, FIB, or PA per 1-SD change in HRV parameters. Therefore, decreased HRV in patients with GC predicts increased burdens of inflammation and coagulation and perturbed nutrition, suggesting that short-term HRV measurement can potentially be a noninvasive biomarker for GC prognosis. INDEX TERMS Gastric cancer, cancer prognosis, heart rate variability, blood biomarker.

show abstract

Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions

Cited by 52 publications

References 71 publications

<p>Gastric Signet Ring Cell Carcinoma: Current Management and Future Challenges</p>

<p>Gastric Signet Ring Cell Carcinoma: Current Management and Future Challenges</p>

<p>The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric Cancer</p>

Short-Term Heart Rate Variability and Blood Biomarkers of Gastric Cancer Prognosis

Contact Info

Product

Resources

About